Business Wire

Synteract Acquires Dermatology Specialist CRO Cu-Tech, Adding Center of Development in Dermatology

Del

Synteract, an innovative contract research organization (CRO) providing full-service Phase I-IV clinical trials, has acquired Cu-Tech, LLC, the leading dermatology specialist CRO. In coming together with Cu-Tech, Synteract has created a dedicated center of dermatology development, making the combined company the leading midsized global CRO for dermatology clinical trials.

Cu-Tech is an industry-renowned dermatology CRO with more than two decades of experience, having managed 130+ dermatology trials. The New Jersey-based CRO is known for its strong relationships with its clients and investigative sites, as well as for its expertise in working across a variety of dermatological indications.

Steve Powell, CEO of Synteract, says, “The acquisition of Cu-Tech represents the next step in our strategy to specialize in targeted areas of clinical development. We have combined Synteract’s existing base of experience in dermatology with the focused strength and expertise that Cu-Tech has provided its customers for over 20 years. Dermatology is poised for continued strong growth, and in acquiring Cu-Tech, we have created a leading CRO for dermatological services and site connections. In recognition of their leadership in the dermatology sector, we will support the Cu-Tech team in their current form. Dermatology is now our fifth specialized area of focus, alongside oncology, neuro-degenerative diseases, rare and orphan diseases, and pediatrics.”

With over 120 dermatologic trials conducted including more than 17,000 patients, Synteract draws on a longstanding dedication to dermatological drug development in complex Phase I-IV clinical trials. By adding a center of development in dermatology, Synteract has positioned itself to better meet sponsors’ specific needs, including addressing stringent trial demands, delivering consistency of study conduct across investigational sites and ensuring accuracy in reporting. Synteract brings international delivery capabilities to the relationship with Cu-Tech as well as specific services in feasibility, biostatistics, clinical operations, data management, medical writing and regulatory expertise.

Kathleen (Kit) Ashenfelter, executive director of operations and development at Cu-Tech, who will now also serve as the head of the Synteract dermatology center of development, says, “Cu-Tech has always offered best-in-class results. We are committed to maintaining the high quality of service that clients and investigative sites have come to expect. Working with Synteract allows us to bring enhanced capabilities to our clients, including an international presence.”

Jack Shannon, Synteract’s chief commercial officer, adds, “Dermatology is a growing area of clinical development worldwide. The combination of Cu-Tech and Synteract creates the leading dermatology CRO with global capabilities and unparalleled access to sites and patients. Our focus on the development of novel and in-demand dermatology drugs provides our customers with dedicated research services that are unmatched in the market.”

About Synteract

With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in its centers of development in oncology and neuro-degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies, and now dermatology. Connect on LinkedIn and Twitter.

Contact information

For Synteract
Beth Walsh, 760-230-2424
beth@clearpointagency.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Bank of Singapore is the First Singapore Private Bank to Receive Regulatory Approval to Open a Wealth Management Subsidiary in Luxembourg16.7.2018 09:36Pressemelding

Bank of Singapore today announced that it has been granted an investment company licence to operate a wealth management subsidiary in Luxembourg – a first for a Singapore private bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005252/en/ (Photo: BOSWM) Bank of Singapore, through this new subsidiary, BOS Wealth Management Europe Société Anonyme (S.A.), will be able to offer a comprehensive range of customised private banking solutions and investment advisory services to its ultra-high and high net worth clients in the European Economic Area (“EEA”) and the United Kingdom (“UK”). The EEA comprises the European Union (EU) countries and Iceland, Liechtenstein and Norway. Currently, Bank of Singapore serves its European clients from its Singapore headquarters and through its parent company OCBC Bank’s London office. There has been robust growth in assets under management from EEA clients as they hold Singapore in high

Primex Pharmaceuticals Appoints Tomaso Dameno as Head of Operations16.7.2018 09:02Pressemelding

Mr. Dameno brings more than 15 years of experience in the pharmaceutical industry to Primex Pharmaceuticals. Most recently, he was Partner and Head of Global Pharma Compliance Operations at PQE Suisse. He has held various pharma line management roles at e.g. Zambon and Helsinn. “I am excited to join Primex at this fast growth stage of its development and on the brink of such an important product launch on the pediatric anesthetic market. My extensive knowledge of the different aspects of the pharmaceutical business will help smooth the path to new markets,” says Tomaso Dameno. Mr. Dameno’s key responsibilities are strategic and operative performance ensuring the development of the global supply chain, heading the regulatory, quality and pharmaceutical safety management functions, as well as contract manufacturing and logistics. He will be part of the Executive Team headed by CEO Kari Sarvanto in Zug, Switzerland. Mr. Sarvanto comments: “I am pleased to see Primex is constantly able to

Orange Acquires Basefarm Holding and Becomes a European Leader in Cloud Computing Services for the Enterprise Sector16.7.2018 07:22Pressemelding

Following a competitive tender process initiated by Abry Partners for its stake in Basefarm, the Orange Group, through its enterprise subsidiary Orange Business Services, has announced today the signature of a contract to acquire 100% of the company’s capital for an enterprise value of 350 million euros. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005214/en/ Basefarm is a leading European player in cloud-based infrastructure and services, as well as the management of critical applications and data analysis. The company, which recorded revenues of over 100 million euros in 2017, has enjoyed strong growth since 2015. Basefarm has a strong operational presence in several European countries, particularly in Norway, Sweden, the Netherlands, Austria and in Germany, where it boasts a cutting-edge big data activity. Its business proposition lies at the forefront of the most innovative services in cloud computing, Big Data a

Spirit AeroSystems and Norsk Titanium Announce Start of Production Qualification for Commercial Aircraft Parts16.7.2018 07:00Pressemelding

Spirit AeroSystems [NYSE: SPR] and Norsk Titanium US Inc. (NTi), have reached an agreement to initiate qualification of Spirit’s first additive-manufactured, titanium, structural component for the Boeing 787. This qualification will validate NTi’s production and industrialization processes, integrate Spirit’s workscope of machining final parts from additively manufactured near-net shapes and verify material and final part conformity to requirements. “Spirit has had a comprehensive and long relationship with Norsk Titanium, and this part will be our first additive structural titanium component incorporated into a commercial airplane program,” said Spirit AeroSystems Senior Vice President of Fabrication and Supply Chain Management, Ron Rabe. NTi is the world’s first FAA-approved, OEM qualified, supplier of additive-manufactured, structural titanium components. NTi’s proprietary Rapid Plasma Deposition™ (RPD™) process has been in serial production of Boeing 787 titanium components since A

New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed Fluid Management in Patients Undergoing Colorectal Surgery16.7.2018 05:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to goal-directed fluid management (GDFM) using Masimo PVi® (pleth variability index, measured noninvasively and continuously using SET® pulse oximetry sensors) in patients undergoing elective colorectal surgery. The primary points of comparison were the amount of crystalloids administered and blood lactate and serum creatinine levels during the intraoperative period.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180715005048/en/ Masimo Radical-7® with PVi®, SpHb®, and RD rainbow SET™ Sensor (Photo: Business Wire) In the study, Dr. Cesur and colleagues, noting the importance of intraoperative fluid management in terms of postoperative organ perfusion and complications, sought to compare the effects of CFM (guided by clinical asse

Alipay and Singapore Tourism Board join hands to boost Chinese tourist spending16.7.2018 02:00Pressemelding

Alipay, the world’s leading mobile and online payment and lifestyle platform operated by Ant Financial Services Group, together with the Singapore Tourism Board (STB), have launched a series of joint marketing initiatives aimed at raising destination awareness of Singapore and driving tourist spending among Chinese visitors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180715005021/en/ Alipay and STB signed a Memorandum of Understanding (MOU) in September 2017 to enhance Chinese tourists’ overall experience in Singapore. Under the MOU, both parties agreed, among other things, to explore co-investing in joint-marketing initiatives to encourage Chinese tourists to spend with Alipay while in Singapore. Since signing the MOU, Alipay has experienced double-digit growth in user spending. China has also become Singapore’s top market in 2017 for both tourism receipts and visitor arrivals, contributing S$4.2 billion in tourism rece